ClinicalTrials.gg
CompletedNCT02500472Updated Apr 4, 2018

Investigation of Kava Effects on NNK Metabolism

An interventional study of Kava in Tobacco Smoking, sponsored by Masonic Cancer Center, University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-04.

Sponsored by Masonic Cancer Center, University of Minnesota · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Tobacco Smoking with a site in United States — 24 open to participants now, 30 under way, 2 of them phase 3. Tobacco Smoking · United States.

Enrollment
150th of 178
24 · median 111
Started
2015
with 4 others
No phase
144 of 186
17 open now
Registered
29th of 186
by date

Among the 186 studies in Tobacco Smoking with a site in United States, this one is the 150th largest by enrollment of the 178 interventional ones that give a count, is one of 5 that started in 2015, is one of 144 with no phase, and was the 29th registered.

Tobacco Smoking

265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.

Browse Tobacco Smoking studies →

Open to participants now

24 of the 186 studies in Tobacco Smoking with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Tobacco Smoking studies recruiting now, 15 (44%) set no upper age limit and 17 (50%) stop at 75 or younger; 2 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Tobacco Smoking with a site in United States, or all of them as a file.
02

Study summary

This is a non-therapeutic, single-arm pilot clinical trial in adult healthy smokers to assess whether kava can alter NNK metabolism in humans.

03

Conditions studied

  • Tobacco Smoking

Keywords

  • Tobacco
  • Smoking
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult ≥ 18 years
  • Current smoker of ≥ 5 cigarettes daily, determined by self-report
  • Adequate liver and kidney function, defined as:

    • , alkaline phosphatase, , and AST within normal limits
    • Creatinine \<1.2
  • Adequate , defined as a hemoglobin ≥12 mg/dL for men and ≥11 for women.
  • Ability and willingness to abstain from all medication and dietary supplements for 3 days prior to kava administration, continuing until a minimum of 7 days after kava administration. Topical medications and inhaled medications that do not contain are permitted.
  • Ability and willingness to completely abstain from alcohol consumption for 3 days prior to kava administration, continuing until a minimum of 7 days after kava administration
  • Ability to understand the nature of the study and provide
  • Willingness to take kava supplement as instructed

Exclusion criteria

Exclusion Criteria:

  • Known hepatobiliary disease or impairment
  • History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect the absorption of kava
  • Chronic medication use that cannot be safely stopped
  • Use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco, cigars, pipes)
  • Major or chronic medical medical disease, including heart disease, poorly controlled diabetes, etc., to be adjudicated by the principal investigator
  • Women who are pregnant, intend to become pregnant within 3 months of the study period, or who are breastfeeding
  • Current or recent (within 12 months) problems with drug use or alcohol dependence by self-report
  • Antibiotic use within 2 months of study enrollment by self-report
  • Alcohol dependence, abuse, or history of dependence/abuse by self-report
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Kava Supplement

    See intervention description.

    Dietary Supplement: Kava

Interventions

  • Dietary supplementPiper methysticum rootStudies of Piper methysticum rootPiper methysticum root pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.

06

What researchers measure

Primary outcomes

  1. Urinary level (nmol/mL) of total NNAL before and after short-term kava administration

    Compare urinary level of total NNAL before and after short-term kava administration

    Time frame: Day 1

  2. Urinary level (nmol/mL) of total NNAL before and after short-term kava administration

    Compare urinary level of total NNAL before and after short-term kava administration

    Time frame: Day 2

  3. Urinary level (nmol/mL) of total NNAL before and after short-term kava administration

    Compare urinary level of total NNAL before and after short-term kava administration

    Time frame: Day 4

  4. Urinary level (nmol/mL) of total NNAL before and after short-term kava administration

    Compare urinary level of total NNAL before and after short-term kava administration

    Time frame: Day 5

  5. Urinary level (nmol/mL) of total NNAL before and after short-term kava administration

    Compare urinary level of total NNAL before and after short-term kava administration

    Time frame: Day 6

  6. Urinary level (nmol/mL) of total NNAL before and after short-term kava administration

    Compare urinary level of total NNAL before and after short-term kava administration

    Time frame: Day 7

Secondary outcomes

  1. Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration

    Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration

    Time frame: Day 1

  2. Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration

    Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration

    Time frame: Day 2

  3. Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration

    Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration

    Time frame: Day 4

  4. Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration

    Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration

    Time frame: Day 5

  5. Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration

    Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration

    Time frame: Day 6

  6. Ratio of urinary NNAL-gluc (nmol/mL) and free NNAL (nmol/mL) before and after short-term kava administration

    Compare the ratio of urinary NNAL-gluc and free NNAL before and after short-term kava administration

    Time frame: Day 7

  7. Percentage of subjects experiencing any particular adverse event

    Determine the safety of short-term kava administration in healthy smokers

    Time frame: Day 4

  8. Percentage of subjects experiencing any particular adverse event

    Determine the safety of short-term kava administration in healthy smokers

    Time frame: Day 7

  9. O6-mG adducts level (fmol) in peripheral blood cells before and after short-term kava administration

    Quantify O6-mG adducts in peripheral blood cells before and after short-term kava administration

    Time frame: Day 4

  10. O6-mG adducts level (fmol) in peripheral blood cells before and after short-term kava administration

    Quantify O6-mG adducts in peripheral blood cells before and after short-term kava administration

    Time frame: Day 7

07

Study locations

1 site
  • Masonic Cancer Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
08

References and documents

Publications

  • Wang Y, Fujioka N, Xing C. Quantitative profiling of cortisol metabolites in human urine by high-resolution accurate-mass MS. Bioanalysis. 2018 Dec;10(24):2015-2026. doi: 10.4155/bio-2018-0182. Epub 2018 Nov 6. PubMed 30412681 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Mar 2018, 27 months.

Of 112 non-industry interventional studies with no phase under Tobacco Smoking, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 27 months is above that.

Counting every sponsor, half of 152 studies reached it within 16 months; a quarter within 4 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2015
First posted
Jul 16, 2015
StartActual
Dec 3, 2015
Primary completionActual
Mar 2018
CompletionActual
Mar 2018
Last update
Apr 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02500472
Responsible party
Sponsor
First posted
Jul 16, 2015
Start date
Dec 3, 2015
Primary completion
Mar 2018
Completion
Mar 2018
Last update
Apr 4, 2018

Study contacts

Naomi Fujioka, MD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piper methysticum root

Start the discussion